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Abstract
Objective This study aimed to examine the efficacy and
safety of nepafenac ophthalmic suspension compared to
placebo in the management of postoperative inflamma-
tion and ocular pain in Japanese patients undergoing
cataract surgery.
Methods This was a multicenter, randomized, double-
masked, placebo-controlled clinical study. Patients received
nepafenac or placebo TID beginning 1 day before cataract
surgery and continuing on the day of surgery for 14 days.
One additional drop was administered on the day of
surgery. The primary efficacy variables were the
percentage of patients cured at postoperative day 14
visit (cure defined as aqueous cells score+aqueous flare
score=0) and the percentage of patients who were pain
free at all postoperative visits.
Results The cure rate on day 14 after surgery was 71.4% (75/
105) in the nepafenac group and 28.6% (30/105) in the
placebo group, showing a significant difference in cure rate
between groups. The nepafenac group demonstrated higher
cure rates than those in the placebo group, with a significant
difference in cure rate on days 7 and 14 postoperatively. The
ocular pain-free rate was 96.2% (102/106) in the nepafenac
group and 67.6% (71/105) in the placebo group, showing a
significant difference between groups. Concerning adverse
events (AEs), 26 AEs were reported in 21 subjects (19.6%) in
the nepafenac group and 31 AEs were reported in 24 subjects
(22.4%) in the placebo group.
Conclusion Nepafenac ophthalmic suspension is a non-
steroidal anti-inflammatory drug effective in the preven-
tion of postoperative inflammation and ocular pain
associated with cataract surgery.
Keywords Japanese . Nepafenac . Placebo control .
Postoperative inflammation . Ocular pain
Introduction
Nepafenac is a nonsteroidal anti-inflammatory drug
(NSAID) and a prodrug that is metabolized into its active
form, amfenac, following ocular administration. Delivering
amfenac as a prodrug permits increased corneal penetration
and high aqueous concentration of the compound [1].
Amfenac suppresses prostaglandin production by inhibiting
cyclooxygenase (COX), as do other NSAIDs [1]. Following
the administration of diclofenac, total prostaglandin pro-
duction by the rabbit iris–ciliary body was inhibited by
approximately 40% within 5 min and remained unchanged
thereafter, while nepafenac exhibited an inhibitory effect on
prostaglandin production between 5 and 10 min after
administration, with the inhibitory rate exceeding 90%
between 40 and 80 min after administration [2]. The
inhibitory effect of nepafenac on extravascular protein
exudation into the aqueous humor of the rabbit continued
for 8 h after administration while diclofenac inhibited
vascular permeation up to 4 h after administration but
exhibited no significant inhibitory effect 8 h after administra-
tion [2]. Since its launch in the USA in 2005, nepafenac
0.1% has been widely used in clinical practice in more than
70 countries worldwide.
To receive marketing approval for the drug in Japan, we
conducted a placebo-controlled, multicenter trial to evaluate
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Nepafenac ophthalmic suspension containing 1 mg of
nepafenac (Fig. 1) per 1 ml and placebo with the same
formulation as nepafenac suspension excluding nepafenac
ingredient supplied in identical, opaque 5-ml bottles.
Study design
This was a multicenter, randomized, double-masked,
placebo-controlled study conducted at 11 Japanese sites
(Table 1) from August 2006 to December 2006. This study
was conducted in accordance with the Declaration of
Helsinki with approval from the institutional review boards.
Patients were randomly assigned to receive nepafenac or
placebo. Patients instilled one drop in the operative eye
three times a day. They began dosing 1 day before surgery
and continued on the day of surgery and for 14 days
thereafter. On the day of surgery, an additional dose was
administered before surgery. The use of other NSAIDs and
steroids were prohibited. The test drugs are blinded to the
investigators and subjects except for the appointed control-
ler of study drugs.
Subjects
Patients 20 years of age or older scheduled to undergo
cataract extraction by PEA and implantation of an
intraocular lens (IOL) were eligible for the study. Each
patient was given sufficient explanation about the
purpose and details of the study and provided written
consent to participate in the study. Patients were
excluded from enrollment if they used topical ocular
or systemic steroids within 14 days of surgery or used
topical ocular or systemic NSAIDs within 7 days of
surgery, except an allowed daily dose of low-dose
aspirin. Patients were also excluded if they planned to
have cataract surgery in their fellow, non-study eye
before the 14-day postoperative study visit or had any
cells, flare, or ocular pain in the operative eye at the
screening examination, had planned multiple surgical
procedures, exfoliation syndrome, ocular trauma, inflam-
matory eye disease, diabetic retinopathy which needed
medical treatment, and uncontrolled diabetes mellitus, or had
grade 3 or higher cataracts according to Emery–Little
classification [3].
Examination items and schedule
The examination schedule is shown in Table 2. Best-corrected
visual acuity (BCVA) and intraocular pressure (IOP)
measurement, ocular pain assessment, slit lamp exami-
nation, and laser flare cell meter (LFCM) measurement
were performed before and 1, 3, 7, and 14 days after
surgery. A fundus examination was performed before
and 7 and 14 days after surgery. Blood pressure/pulse
rate measurement was performed before and at the day
of surgery and 1, 3, 7, and 14 days after surgery. A
laboratory examination was performed before and
14 days after surgery.
Efficacy evaluation
The grading criteria and scale for clinical symptom and
signs are summarized in Table 3. The criteria and scale
are the same as previous analysis of nepafenac [4–6].
Patients who received the test drug, completed surgery,
and had at least one follow-up visit were included in the
intention-to-treat (ITT) analyses. Primary efficacy analy-
ses were conducted on the ITT data set. The primary
efficacy variables were the cure rate (the percentage of
subjects with an aqueous cell score+aqueous flare score=
0) at day 14 after surgery and the ocular pain-free rate (the
percentage of subjects with an ocular pain score of 0) at all
postoperative visits. Also, the cure rate and the ocular
Fig. 1 Chemical structure
of nepafenac
Table 1 Investigators and institutions
No. Institutions Investigators
1 Ohtsuka Eye Hospital Makoto Higuchi
2 Mitani Eye Clinic Kiichiro Mitani
3 Muramatsu Eye Clinic Tomoyuki Muramatsu
4 Nakajima Eye Clinic Toru Nakajima
5 Kikukawa Eye Clinic Koichiro Ikeda
6 Tokai Eye Clinic Yoshihide Nakai
7 Kitano Hospital Isao Saito
8 Nishi Eye Hospital Hiroki Iwanishi
9 Hirota Eye Clinic Atsushi Hirota
10 Ohshima Hospital of Ophthalmology Nobuyuki Yabe
11 Hayashi Eye Hospital Ken Hayashi
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Table 2 The examination schedule





Baseline Day 1 Day 3 Day 7 Day 14 
Study 
discontinuation 
Corrected visual acuity a b b b a a
Intraocular pressure a b b b a a
Fundus examination a b a a
Slit lamp examination a b b b a a
Ocular pain assessment b b b b b b
Blood pressure
and pulse rate   
Laser flare cell meter b b b b b b
Laboratory examination 
Instillation of the 
investigational product 
(-Day 1  Day 14) 
Adverse events
a Both eyes
b Study (operative) eye
Grading criteria
Ocular pain 0: None—absence of pain
1: Trace—slight sensation of pain or discomfort
2: Mild—mild, tolerable aching of the eye
3: Moderate—moderate and prolonged aching sufficient to require the use of analgesics
4: Moderately severe—prolonged intense aching requiring the use of analgesics
5: Severe—prolonged sharp ocular or periocular pain
Flare Use a 1 mm wide beam of the slit lamp aimed at the center of the pupil
0: None—no visible flare when compared with the normal eye
1: Mild—flare visible against dark pupillary background but not visible against iris
background
2: Moderate—flare is visible with the slit lamp beam aimed onto the iris surface as
well as the dark pupillary background
3: Severe very dense flare. May also present as a “hazy” appearance of anterior
segment structures when viewed with low power magnification of the slit lamp.
Presents as a pronounced Tyndall effect
Cell Use narrow slit beam (0.5 mm in width and at least 8 mm in length) at maximum
luminance. Pigment and red blood cells are to be ignored.
0: None
1: 1 to 5 cells
2: 6 to 15 cells
3: 16 to 30 cells
4: Greater than 30 cells
Table 3 Grading criteria for
clinical symptom and signs
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pain-free rate at each postoperative visit were compared
between two groups. The secondary variables were
aqueous cell score, aqueous flare score, cell count, flare
value, and the treatment failure rate (the percentage of
subjects with either an aqueous cell score or an aqueous
flare score of 3 or more, or an ocular pain score of 4 or
more) at each postoperative visit. Cell count and flare
value were measured with LFCM.
Total Nepafenac group Placebo group P valuea
N % N % N %
Total 211 100.0 106 50.2 105 49.8
Gender
Male 98 46.4 49 46.2 49 46.7 0.9489
Female 113 53.6 57 53.8 56 53.3
Age
18 to 64 years 59 28.0 24 22.6 35 33.3 0.0836
≥ 65 years 152 72.0 82 77.4 70 66.7
Emery’s classification
1 50 23.7 28 26.4 22 21.0 0.3508
2 161 76.3 78 73.6 83 79.0
Table 4 Demographic data
(ITT)
a From Chi-square
Table 5 Demographic data by institution (ITT)
Gender Age Emery’s classification
Male Female <65 ≥65 1 2
N % N % N % N % N % N %
Total Nepafenac 49 46.2 57 53.8 24 22.6 82 77.4 28 26.4 78 73.6
Placebo 49 46.7 56 53.3 35 33.3 70 66.7 22 21.0 83 79.0
Investigator no. 1 Nepafenac 4 66.7 2 33.3 2 33.3 4 66.7 4 66.7 2 33.3
Placebo 2 33.3 4 66.7 3 50.0 3 50.0 5 83.3 1 16.7
2 Nepafenac 5 41.7 7 58.3 3 25.0 9 75.0 5 41.7 7 58.3
Placebo 6 50.0 6 50.0 1 8.3 11 91.7 5 41.7 7 58.3
3 Nepafenac 5 33.3 10 66.7 2 13.3 13 86.7 0 0.0 15 100.0
Placebo 6 40.0 9 60.0 2 13.3 13 86.7 0 0.0 15 100.0
4 Nepafenac 6 75.0 2 25.0 0 0.0 8 100.0 6 75.0 2 25.0
Placebo 4 50.0 4 50.0 2 25.0 6 75.0 5 62.5 3 37.5
5 Nepafenac 7 43.8 9 56.3 2 12.5 14 87.5 0 0.0 16 100.0
Placebo 7 43.8 9 56.3 5 31.3 11 68.8 0 0.0 16 100.0
6 Nepafenac 3 60.0 2 40.0 1 20.0 4 80.0 0 0.0 5 100.0
Placebo 2 33.3 4 66.7 3 50.0 3 50.0 0 0.0 6 100.0
7 Nepafenac 2 22.2 7 77.8 2 22.2 7 77.8 2 22.2 7 77.8
Placebo 3 50.0 3 50.0 2 33.3 4 66.7 2 33.3 4 66.7
8 Nepafenac 3 37.5 5 62.5 3 37.5 5 62.5 2 25.0 6 75.0
Placebo 4 44.4 5 55.6 4 44.4 5 55.6 1 11.1 8 88.9
9 Nepafenac 5 55.6 4 44.4 2 22.2 7 77.8 2 22.2 7 77.8
Placebo 5 55.6 4 44.4 5 55.6 4 44.4 2 22.2 7 77.8
10 Nepafenac 4 33.3 8 66.7 3 25.0 9 75.0 6 50.0 6 50.0
Placebo 6 50.0 6 50.0 5 41.7 7 58.3 1 8.3 11 91.7
11 Nepafenac 5 83.3 1 16.7 4 66.7 2 33.3 1 16.7 5 83.3
Placebo 4 66.7 2 33.3 3 50.0 3 50.0 1 16.7 5 83.3
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Safety evaluation
All patients receiving the test drug were included in the safety
analysis. Safety evaluation included incidence of adverse
events (AEs), blood pressure/pulse rate, laboratory tests,
BCVA, IOP, slit lamp examination (bulbar conjunctival
injection, corneal edema, and chemosis), and fundus exami-
nation (retina, macula lutea, choroid, and optic nerve).
Statistical analysis
For the primary variables of cure rate at day 14 and the
ocular pain-free rate at all postoperative visits, a Chi-
square test of independence was conducted to assess the
superiority of nepafenac relative to placebo. Multiplicity
adjustment for the primary endpoints was made by
sequential testing with fixed sequences, in which the
cure rate was analyzed first followed by the ocular pain-free
rate. And a Chi-square test or a Fisher’s exact test was
performed for the cure rate and the ocular pain-free rate at each
study visit.
The analysis of aqueous cells score, flare scores, cell
counts, and flare value was conducted with a repeated
measures analysis of variance at postoperative visits. A
two-sample t test was used for the comparisons in aqueous
cells score and flare score at baseline between two groups.
The comparisons between nepafenac and placebo in
treatment failures at each postoperative visit were made
using nonlinear mixed model with maximum likelihood
estimation from NLMixed procedure of SAS software.
Demographics data were compared between two groups
using by a Chi-square test. A P value less than 0.05
indicated statistical significance. Data analyses were per-
formed using SAS software, version 9.1.
Results
Patient population and demographics
Two hundred fifteen patients, 108 treated with nepafe-
nac and 107 treated with placebo, were enrolled in this
study. One patient discontinued prior to the use of the
study medication for patient decision. Two hundred
fourteen remaining patients received at least one dose of
test drug and were therefore included in the safety
analysis. Three of 214 patients discontinued from the
study prior to or at the time of surgery for patient
decision (n=1), the use of NSAIDs (n=1) and investigator
decision due to surgical difficulties. These three patients
were excluded in the ITT population. A total of 211
patients, 106 treated with nepafenac and 105 treated with
placebo were included in the ITT population.
The demographics data for the patients included in
the ITT data set are summarized in Table 4, and the
demographics data by institution are showed in Table 5.
As indicated in Table 4, there were no statistically
significant differences in gender, age, and Emery’s
classification between treatment groups.
Efficacy
There was a significant difference in cure rate at day 14
between nepafenac (71.4%, 75/105) and placebo
(28.6%, 30/105) (P<0.0001), demonstrating the effec-
tiveness of nepafenac in reducing postoperative inflam-
mation (Table 6). When comparing cure rates at each visit,
nepafenac achieved significantly higher cure rates than
placebo at days 7 and 14 (P<0.0001 for days 7 and 14)
(Table 6). The ocular pain-free rate was 96.2% (102/106) in
the nepafenac group and 67.6% (71/105) in the placebo group,
showing a significant difference between groups (P<0.0001)
(Table 7). The nepafenac group demonstrated significantly
higher ocular pain-free rates than the placebo group at all
postoperative visits (P=0.0051 for day 1, P=0.0003 for
day 3, P=0.0002 for day 7, and P=0.0051 for day 14)
(Table 8). In the nepafenac group, cell scores and flare scores
measured at each postoperative visit decreased as time
elapsed after surgery, showing the suppressive effect of
Treatment Alla (N) Day 1 Day 3 Day 7 Day 14
N % N % N % N %
Nepafenac group 105 2 1.9 22 21.0 53 50.5 75 71.4
Placebo group 105 2 1.9 16 15.2 20 19.0 30 28.6
P value 1.00 0.2822 <0.0001 <0.0001
Table 6 Cure rate at each study
visit (ITT)
Test = Chi-square (Fisher’s ex-
act test if N<5)
a One patient missing cure data
Table 7 Percent ocular pain free (ITT)
Treatment Total Pain free
N N %
Nepafenac group 106 102 96.2
Placebo group 105 71 67.6
Test = Chi-square, P<0.0001
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nepafenac on postoperative inflammation. In contrast, no
marked decrease was observed in either the cell or flare
scores in the placebo group. Significant intergroup differ-
ences were observed in the cell score on day 7 and
subsequent visits (P<0.0001 for days 7 and 14) and in the
flare score on day 3 and subsequent visits (P=0.0041 for
day 3 and P<0.0001 for days 7 and 14) (Tables 9 and 10).
Postoperative cell counts and flare values were measured
with LFCM. Decreases in both cell counts and flare
values were observed on day 3 and subsequent visits in
the nepafenac group, whereas increases in both variables
were observed on day 3 in the placebo group.
Significant intergroup differences were observed in cell
counts and flare values on day 3 and subsequent visits
(Tables 11 and 12).
The incidence of treatment failures 14 days after surgery
was 1.9% (2/106) in the nepafenac group and 8.6% (9/105)
in the placebo group. There were more subjects who had no
response to treatment in the placebo group than in the
nepafenac group, although no significant difference was
observed between groups (Table 13).
Safety
A total of 26 AEs were reported in 21 subjects (19.6%)
in the nepafenac group and 31 AEs were reported in 24
subjects (22.4%) in the placebo group. Two AEs in the
nepafenac group and six AEs in the placebo group were
regarded as adverse reactions (ADRs) for which the
causal relation could not be ruled out. The ADRs
reported in the nepafenac group were foreign body
sensation in the eyes in one subject (0.9%) and eye
discharge in one subject (0.9%), both of which were
mild and non-serious. The ADRs reported in the
placebo group were eye pruritus in one subject (0.9%),
foreign body sensation in the eyes in one subject (0.9%)
subject, eye irritation in two subjects (1.9%), and
increased lacrimation in two subjects (1.9%), all of
which were non-serious. All of the ADRs were mild in
severity, except for moderate foreign body sensation in
the eyes reported in one subject. In the nepafenac
group, no clinically relevant findings were obtained in
other examinations for safety evaluations including
laboratory tests, blood pressure/pulse rate, BCVA, IOP,
slit lamp examination, and fundus examination.
Discussion
In Japan, the ophthalmic preparations of steroids or
NSAIDs are used for the treatment of postoperative
inflammation following cataract surgery. NSAIDs are
also used for the prevention of postoperative cystoid
macular edema (CME). Diclofenac sodium and bromfe-
Treatment All (N) Day 1 Day 3 Day 7 Day 14
N % N % N % N %
Nepafenac group 106 103 97.2 104 98.1 103 97.2 103 97.2
Placebo group 105 91 86.7 88 83.8 85 81.0 91 86.7
P value 0.0051 0.0003 0.0002 0.0051
Table 8 Percentage of patients
with no pain at each study
visit (ITT)
Test = Chi-square
Baseline Day 1 Day 3 Day 7 Day 14
Nepafenac group Mean 0.0 1.3 0.9 0.5 0.3
Std 0.0 0.6 0.7 0.6 0.6
N 106 105 105 105 105
Min 0 0 0 0 0
Max 0 4 4 4 4
Placebo group Mean 0.0 1.2 1.0 1.0 0.9
Std 0.0 0.5 0.7 0.9 0.9
N 105 105 105 105 105
Min 0 0 0 0 0
Max 0 2 4 4 4
P value N/A 0.6905 0.1638 <0.0001 <0.0001
Table 9 Aqueous cells score by
treatment and visit (ITT)
Baseline P value is from t test;
non-baseline P values are
LSMeans by visit; test = repeat-
ed measure ANOVA, main ef-
fect of treatment P<0.0001;
treatment by visit interaction
P<0.0001
Min minimum, Max maximum,
Std standard deviation
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nac have been shown to reduce postoperative inflam-
mation [7–10]. Some studies have shown that aqueous
flare values in the early postoperative period are even
lower in those treated with diclofenac sodium than in
those treated with steroids [11, 12]. Other studies have
demonstrated that NSAIDs are effective in preventing
postoperative CME [13–16], in which an ophthalmic
NSAID was administered for several months after
cataract surgery. Nepafenac is a prodrug metabolized
into its active form, amfenac. Ex vivo inhibition of
prostaglandin synthesis by nepafenac/amfenac was sig-
nificantly greater and of longer duration than diclofenac
[2]. And nepafenac had sixfold greater corneal penetra-
tion than diclofenac [17]. Amfenac was the more potent
COX-2 inhibitor than bromfenac and ketorolac. And the
combined area under the curve of nepafenac and amfenac
was higher than the bromfenac and ketorolac [1].
In this study, nepafenac expected to prevent postopera-
tive inflammation and ocular pain, was administered as a
monotherapy to patients undergoing cataract surgery, and
its efficacy and safety in the management of postoperative
inflammation and ocular pain were compared with those of
a placebo. The subjects were Japanese patients with
cataracts who were undergoing cataract surgery with PEA
and IOL implantation. Evaluations were based on cure rates
14 days after surgery and ocular pain-free rates during the
first 14 days after surgery. The cure rate was 71.4% in the
nepafenac group and 28.6% in the placebo group, showing
a significant difference between groups. Those who
achieved cures in the placebo group appeared to have
undergone spontaneous resolution of postoperative inflam-
mation, as indicated by a gradual increase in cure rates over
the course of treatment. In contrast, the nepafenac group
demonstrated higher cure rates than those in the placebo
group, with significant intergroup differences observed on
days 7 and 14 postoperatively. This study revealed
significant differences in cure rates between nepafenac
and placebo over the course of treatment, which was
consistent with the results of a study conducted in the USA
using the same evaluation [4].
Baseline Day 1 Day 3 Day 7 Day 14
Nepafenac group Mean 0.0 0.9 0.5 0.3 0.1
Std 0.0 0.6 0.6 0.5 0.3
N 106 105 105 105 105
Min 0 0 0 0 0
Max 0 2 2 2 2
Placebo group Mean 0.0 0.9 0.7 0.8 0.6
Std 0.0 0.5 0.7 0.8 0.8
N 105 105 105 105 105
Min 0 0 0 0 0
Max 0 2 3 3 3
P value N/A 0.5793 0.0041 <0.0001 <0.0001
Table 10 Flare score by treat-
ment and visit (ITT)
Baseline P value is from t test;
non-baseline P values are
LSMeans by visit; test = repeated
measure ANOVA, main effect of
treatment P<0.0001; treatment
by visit interaction P<0.0001
Min minimum, Max maximum,
Std standard deviation
Day 1 Day 3 Day 7 Day 14
Nepafenac group Mean 39.2 19.8 9.7 6.0
Std 79.2 25.1 11.2 9.8
N 54 54 54 54
Min 0.0 0.0 0.0 0.0
Max 428.7 116.4 52.7 65.3
Placebo group Mean 40.4 55.3 32.2 24.1
Std 52.8 66.2 37.3 31.4
N 53 54 54 54
Min 0.0 0.0 0.0 0.0
Max 312.2 311.2 177.3 128.0
P value 0.8738 <0.0001 0.0107 0.0394
Table 11 Cell count measured
by LFCM by treatment and
visit (ITT)
Non-baseline P values are
LSMeans by visit; test = repeat-
ed measure ANOVA, main ef-
fect of treatment P=0.0011;
treatment by visit interaction
P=0.0186; cell count was
measured by laser flare cell
meter at six sites
Min minimum, Max maximum,
Std standard deviation
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The use of LFCM in the evaluation of postoperative
inflammation following cataract surgery has been described in
many studies [18–20]. LFCM enables assessment of the
degree of inflammation by quantitatively measuring such
parameters as white blood cell count and protein concentration
in the aqueous humor. This study also included secondary
endpoints that were evaluated with LFCM. Aqueous cell
counts and aqueous flare values asmeasuredwith LFCMwere
significantly lower in the nepafenac than in the placebo group.
The mean flare value in the placebo group reached its peak on
day 7 while no postoperative increase in flare values was
observed in the nepafenac group. Cell scores and flare scores
determined by slit lamp biomicroscopy and flare values and
cell counts measured with LFCM showed similar patterns of
changes over time from day 3 and thereafter, demonstrating
the appropriateness of the efficacy evaluation based on cell
scores and flare scores determined by slit lamp biomicroscopy
and the efficacy of nepafenac in the management of
postoperative inflammation.
Since postoperative inflammation following intraocular
surgery contributes to the development of CME, it is very
important to reduce or resolve postoperative inflammation.
In this study, evaluations were only performed up to
2 weeks after surgery, and thus the preventative effect of
nepafenac on CME was not examined. However, the fact
that the cure rate of nepafenac was significantly higher than
placebo implies that nepafenac is likely to be effective in
preventing the development of CME.
This study also examined the ocular pain after cataract
surgery. The pain-free rate was 96.2% in the nepafenac
group and 67.6% in the placebo group, showing a
significant difference between groups. Most subjects in
the nepafenac group complained of no ocular pain
throughout the study period while more than 30% of the
subjects in the placebo group complained of ocular pain.
These findings also suggest the need for the postoperative
use of agents with an analgesic effect, such as nepafenac
0.1%, in clinical practice.
Reported AEs associated with ophthalmic NSAIDs
include diffuse superficial keratitis, corneal erosion, and
corneal epithelium disorder, and more serious AEs include
corneal ulcer and corneal perforation [21]. In this study, no
clinically significant AEs associated with nepafenac were
reported, and the incidences of AEs and ADRs in the
nepafenac group were lower than those in the placebo
group, demonstrating the favorable safety profile of
nepafenac.
Conclusion
Nepafenac ophthalmic suspension 0.1% is significantly
more effective than the placebo in the management of
postoperative inflammation and ocular pain following
cataract surgery and thus is considered an essential NSAID
in ophthalmic surgery.
Day 1 Day 3 Day 7 Day 14
Nepafenac group Mean 20.6 20.6 13.4 11.4
Std 24.6 40.9 12.2 9.1
N 101 103 103 103
Min 0.5 0.3 0.4 0.3
Max 153.2 396.7 57.8 57.8
Placebo group Mean 24.3 47.5 65.6 52.0
Std 34.4 49.8 77.7 69.9
N 101 104 104 104
Min 1.8 2.5 2.5 1.5
Max 307.6 333.9 479.7 479.7
P value 0.6201 <0.0001 <0.0001 <0.0001
Table 12 Flare value measured
by LFCM by treatment and
visit (ITT)
Non-baseline P values are
LSMeans by visit; test = repeated
measure ANOVA, main effect of
treatment P<0.0001; treatment
by visit interaction P<0.0001
Min minimum, Max maximum,
Std standard deviation
Treatment Total Day 1 Day 3 Day 7 Day 14
N N % N % N % N %
Nepafenac group 106 2 1.9 2 1.9 2 1.9 2 1.9
Placebo group 105 0 0.0 1 1.0 9 8.6 9 8.6
P value 0.5467 0.3974 0.2001 0.2236
Table 13 Incidence of treat-
ment failures at each study visit
(ITT)
NLMixed model P=0.6151;
main effect of treatment; failure
defined as aqueous cells score
≥3 or aqueous flare score = 3 or
ocular pain score ≥4
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